BIBF 1120 (Nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer

Lignende værker

• Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120)
  af: Huang, Ruby Yun-Ju, et al.
  Udgivet: (2015)
• Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
  af: Antoniu, Sabina A
  Udgivet: (2012)
• Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer
  af: Awasthi, Niranjan, et al.
  Udgivet: (2014)
• Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo
  af: Xue, Cong, et al.
  Udgivet: (2016)
• Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
  af: Hilberg, Frank, et al.
  Udgivet: (2018)